Discover
NUVB
Nuvation Bio Inc.
5.85
4800 x 5.84
5200 x 5.85
bid
ask
-
0.22
3.62%
5000 @ 07:30 PM
5.90 +0.05 (0.85%)
| Ytd | -34.71% | |
| 1y | 84.54% |
5.82
day range
6.18
3.01
52 week range
9.54
| Open | 6.15 | Prev Close | 6.07 | Low | 5.82 | High | 6.18 | Mkt Cap | 2.05B |
| Vol | 4.43M | Avg Vol | 6.84M | EPS | -0.44 | P/E | N/A | Forward P/E | -389.67 |
| Beta | 1.53 | Short Ratio | 9.88 | Inst. Own | 67.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-02 | 50-d Avg | 6.42 | 200-d Avg | 5.91 | 1yr Est | 13.10 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-02 | 2026-09 | -0.12 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.14 | -0.15 | -0.01 | -5.89% |
| 2026-05-04 | 2026-03 | -0.03 | 0.01 | 0.04 | 135.66% |
| 2026-03-02 | 2025-12 | -0.11 | -0.11 | N/A | N/A |
| 2025-11-03 | 2025-09 | -0.17 | -0.16 | 0.01 | 5.88% |
| 2025-08-07 | 2025-06 | -0.17 | -0.17 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-16 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-09-16 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-08-21 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2026-08-18 | JP Morgan | Upgrade | Overweight | |
| 2026-08-07 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-07-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-11-18 | HANLEY DAVID C | Chief Technology Officer | 24.00K | Sale |
| 2025-06-15 | HUNG DAVID T | Chief Executive Officer | 59.28M | Purchase |
| 2026-04-16 | LIU DONGFANG | Officer | 18.00K | Sale |
| 2026-02-26 | MAKUNJE MOSES | Officer | 68.14K | Stock Award(Grant) |
| 2026-06-22 | MARKEL STACY | Officer | 32.59K | Sale |
| 2026-06-08 | MASHAL ROBERT | Director | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 52.23M | 305.29M | 14.88% |
| 2026-06-29 | Blackrock Inc. | 27.63M | 161.50M | 7.87% |
| 2026-06-29 | Decheng Capital LLC | 25.95M | 151.70M | 7.39% |
| 2026-06-29 | Vanguard Capital Management LLC | 11.92M | 69.67M | 3.39% |
| 2026-06-29 | Omega Fund Management, Llc | 8.08M | 47.23M | 2.30% |
| 2026-06-29 | Laurion Capital Management, LP | 7.82M | 45.71M | 2.23% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 17.55M | 102.55M | 5.00% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 8.85M | 51.72M | 2.52% |
| 2026-07-30 | iShares Trust-iShares Russell 2000 ETF | 6.43M | 37.57M | 1.83% |
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 4.94M | 28.88M | 1.41% |
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 4.52M | 26.44M | 1.29% |
| 2026-06-29 | American Century Mutual Funds, Inc.-Small Cap Growth Fund | 3.42M | 20.01M | 0.98% |